Relay Therapeutics (RLAY) 10-Q2023 Q3 Quarterly report

Filed: 2 Nov 23, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: agnostic, comparison, constraint, cORR, ESMO, FGFR, lirafugratinib, objective, pause, refundable, triplet

Removed: noted, opt, registrational, repayment, shared, single, variant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RLAY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Relay Therapeutics, Inc. (the “Company”) for the quarter ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 2, 2023	By:	/S/ SANJIV K. PATEL
		Sanjiv K. Patel
		President and Chief Executive Officer (Principal Executive Officer)


Date: November 2, 2023	By:	/S/ THOMAS CATINAZZO
		Thomas Catinazzo
		Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.